|
|
Vaccine Detail
|
117-126:FGF-5 Peptide |
| Vaccine Information |
- Vaccine Name: 117-126:FGF-5 Peptide
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007187
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: FGF-5
- FGF5
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: This vaccine is prepared by having a renal cell caricoma cell line to overexpress FGF-5 (Dalet et al., 2011).
- Description: A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5 (Dalet et al., 2011), FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04) (NCIT_C28780).
This vaccine has been used in trials involving renal cancer.
|
| Host Response |
|
|
| References |
Dalet et al., 2011: Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. European journal of immunology. 2011; 41(1); 39-46. [PubMed: 21182075].
NCIT_C28780: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28780]
|
|
